profit from every $100 of sales.
$0$100
Rocket Pharmaceuticals
$2.30-3.77% today
-27.4% in 1 year
1-year low $2.181-year high $5.30
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Rocket Pharmaceuticals sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$223 million of profit last year.
SalesProfit
Rocket Pharmaceuticals vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Rocket Pharmaceuticals | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Rocket Pharmaceuticals's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -224 | -260 | -273 | -229 | |
| -214 | -237 | -247 | -210 | |
| -222 | -246 | -259 | -223 | |
| -3.26 | -2.92 | -2.73 | -2.01 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 552 | 566 | 528 | 330 |
| Cash | 141 | 56 | 164 | 78 |
| Total debt | 23 | 25 | 25 | 25 |
| Total liabilities | 62 | 74 | 64 | 53 |
| 490 | 493 | 463 | 277 | |
| 68 | 84 | 95 | 111 | |
| -33.9% | -37.2% | -41.5% | -57.9% | |
| -45.3% | -49.9% | -55.9% | -80.5% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -178 | -195 | -210 | -190 | |
| 9 | 16 | 6 | 0 | |
| -187 | -211 | -216 | -190 | |
| Dividends paid | – | – | – | – |
| 0 | 0 | 0 | 0 | |
| 31 | 39 | 44 | 37 |
Valuation
- –
- –
- –
- 1.5×
- –
- –
- –
- -75.4%
- -88.4%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -81.8%
- -50.6%
- -70.8%
- -73.4%
- -82.7%
- –
Growth
- –
- –
- +11.7%
- –
- +15.1%
Financial health
- 0.1×
- 0.10
- 8.7%
- -45.7×
- 6.12
- 6.12
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 1%of 952
Bottom 20%of 884
Bottom 1%of 987
What analysts expect
- Average price target
- $5.00
- Range
- $5.00 – $5.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 7, 2026 | -0.42 | -0.41 | −2.4% |
| Feb 26, 2026 | -0.38 | -0.42 | +9.5% |
| Nov 6, 2025 | -0.45 | -0.48 | +6.2% |
| Aug 7, 2025 | -0.59 | -0.57 | −3.5% |
| May 8, 2025 | -0.56 | -0.59 | +5.1% |
| Feb 27, 2025 | -0.62 | -0.68 | +8.8% |
| Nov 7, 2024 | -0.71 | -0.78 | +9.0% |
| Aug 5, 2024 | -0.74 | -0.74 | +0.0% |
News
Rocket Lab and The Trade Desk Are 2 Beaten-Down Stocks to Buy Before 2027Yahoo Finance · Nov 10, 2026Rocket Lab shares dip after the company’s ‘defining’ quarter misses the markMarketWatch · Nov 9, 2026Rocket Lab Stock Has Lost About 70% From Its Record. Is It Finally a Buy?Yahoo Finance · Nov 6, 2026Why Rocket Lab Stock Plunged 15% in October and Why Its Decline Might Be Short-LivedYahoo Finance · Nov 5, 2026Rocket Lab's Backlog Is $2.36 Billion -- More Than Double Its 2026 Revenue -- and the Stock Still Fell 38% This Month. Here's the Disconnect.Yahoo Finance · Oct 31, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
29No pass
Benjamin Graham
59No pass
Philip Fisher
33No pass
Peter Lynch
58No pass
Joel Greenblatt
0No pass
Charlie Munger
28No pass
Terry Smith
26No pass
Questions about Rocket Pharmaceuticals
Is Rocket Pharmaceuticals a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Rocket Pharmaceuticals AI analysis
What does Rocket Pharmaceuticals do?
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It is in Biotechnology.
Does Rocket Pharmaceuticals pay a dividend?
No. Rocket Pharmaceuticals does not pay a dividend at the moment; in 2025 it returned $67,000 to shareholders by buying back its own shares.
Is Rocket Pharmaceuticals stock halal?
Questionable. Rocket Pharmaceuticals sits in a grey zone: its cash and confirmed interest-bearing investments are 31% of its market value, between 30% and 33%. How we check
How has Rocket Pharmaceuticals stock done over the past year?
Down 27.4% over the past twelve months, to $2.30. It traded between $2.18 and $5.30 and is 56.6% below its high.
Who are Rocket Pharmaceuticals's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Rocket Pharmaceuticals's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.